Press release
Hypercoagulability Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Yuhan Corp, Dexa Medica Group, Asahi Kasei Pharma, Kyowa Kirin Co., Takeda, Octapharma
The Key Hypercoagulability Companies in the market include - Yuhan Corporation, Dexa Medica Group, Asahi Kasei Pharma Corporation, Kyowa Kirin Co., Ltd., Takeda, Octapharma, Instituto Grifols, S.A., and others.DelveInsight's "Hypercoagulability Market Insights, Epidemiology, and Market Forecast-2032 report offers an in-depth understanding of the Hypercoagulability, historical and forecasted epidemiology as well as the Hypercoagulability market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Hypercoagulability, offering comprehensive insights into the Hypercoagulability revenue trends, prevalence, and treatment landscape. The report delves into key Hypercoagulability statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Hypercoagulability therapies. Additionally, we cover the landscape of Hypercoagulability clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Hypercoagulability treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Hypercoagulability space.
To Know in detail about the Hypercoagulability market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Hypercoagulability Market Forecast [https://www.delveinsight.com/sample-request/hypercoagulability-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Hypercoagulability Market Report:
*
The Hypercoagulability market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
*
Key Hypercoagulability Companies: Yuhan Corporation, Dexa Medica Group, Asahi Kasei Pharma Corporation, Kyowa Kirin Co., Ltd., Takeda, Octapharma, Instituto Grifols, S.A., and others
*
Key Hypercoagulability Therapies: Anplag, DLBS1033, ART-123, KW-3357, TAK-662, Atenativ, Antithrombin III, and others
*
The Hypercoagulability market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Hypercoagulability pipeline products will significantly revolutionize the Hypercoagulability market dynamics.
*
Hypercoagulability (also called thrombophilia) affects ~5-15% of the general population, depending on genetic and acquired risk factors
*
Common inherited forms include Factor V Leiden mutation (present in ~5% of Caucasians) and prothrombin gene mutation (~2-3%)
*
Hypercoagulable states contribute significantly to VTE, which has an annual incidence of ~1-2 per 1,000 people
*
Patients with thrombophilia have a 3-8 times higher lifetime risk of deep vein thrombosis (DVT) or pulmonary embolism (PE)
*
Patients with a prior thrombotic event and underlying thrombophilia face higher recurrence rates without long-term anticoagulation
Hypercoagulability Overview
Hypercoagulability (also called thrombophilia) is a condition where the blood has an increased tendency to clot (form thrombi) abnormally. This can be due to inherited factors (like Factor V Leiden mutation or prothrombin gene mutation) or acquired conditions (such as cancer, pregnancy, obesity, or antiphospholipid syndrome).
It raises the risk of dangerous clots in veins or arteries, leading to complications like deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, or heart attack.
Treatment often involves blood thinners (anticoagulants) to reduce clot risk. Let me know if you want a breakdown of causes or symptoms!
Get a Free sample for the Hypercoagulability Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/hypercoagulability-market [https://www.delveinsight.com/report-store/hypercoagulability-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hypercoagulability Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Hypercoagulability Epidemiology Segmentation:
The Hypercoagulability market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
*
Total Prevalence of Hypercoagulability
*
Prevalent Cases of Hypercoagulability by severity
*
Gender-specific Prevalence of Hypercoagulability
*
Diagnosed Cases of Episodic and Chronic Hypercoagulability
Download the report to understand which factors are driving Hypercoagulability epidemiology trends @ Hypercoagulability Epidemiology Forecast [https://www.delveinsight.com/sample-request/hypercoagulability-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hypercoagulability Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Hypercoagulability market or expected to get launched during the study period. The analysis covers Hypercoagulability market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Hypercoagulability Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Hypercoagulability Therapies and Key Companies
*
Anplag: Yuhan Corporation
*
DLBS1033: Dexa Medica Group
*
ART-123: Asahi Kasei Pharma Corporation
*
KW-3357: Kyowa Kirin Co., Ltd.
*
TAK-662: Takeda
*
Atenativ: Octapharma
*
Antithrombin III: Instituto Grifols, S.A.
Discover more about therapies set to grab major Hypercoagulability market share @ Hypercoagulability Treatment Landscape [https://www.delveinsight.com/sample-request/hypercoagulability-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Hypercoagulability Market Drivers
*
Rising Prevalence of Thrombotic Disorders
*
Advancements in Anticoagulant Therapies
*
Increased Awareness and Early Diagnosis
*
Expansion of Healthcare Infrastructure
*
Aging Population
Hypercoagulability Market Barriers
*
High Cost of Treatment
*
Risk of Bleeding Complications
*
Limited Access in Rural Areas
*
Regulatory Challenges
*
Patient Non-compliance
Scope of the Hypercoagulability Market Report
*
Study Period: 2019-2032
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Hypercoagulability Companies: Yuhan Corporation, Dexa Medica Group, Asahi Kasei Pharma Corporation, Kyowa Kirin Co., Ltd., Takeda, Octapharma, Instituto Grifols, S.A., and others
*
Key Hypercoagulability Therapies: Anplag, DLBS1033, ART-123, KW-3357, TAK-662, Atenativ, Antithrombin III, and others
*
Hypercoagulability Therapeutic Assessment: Hypercoagulability current marketed and Hypercoagulability emerging therapies
*
Hypercoagulability Market Dynamics: Hypercoagulability market drivers and Hypercoagulability market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Hypercoagulability Unmet Needs, KOL's views, Analyst's views, Hypercoagulability Market Access and Reimbursement
To know more about Hypercoagulability companies working in the treatment market, visit @ Hypercoagulability Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/hypercoagulability-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Hypercoagulability Market Report Introduction
2. Executive Summary for Hypercoagulability
3. SWOT analysis of Hypercoagulability
4. Hypercoagulability Patient Share (%) Overview at a Glance
5. Hypercoagulability Market Overview at a Glance
6. Hypercoagulability Disease Background and Overview
7. Hypercoagulability Epidemiology and Patient Population
8. Country-Specific Patient Population of Hypercoagulability
9. Hypercoagulability Current Treatment and Medical Practices
10. Hypercoagulability Unmet Needs
11. Hypercoagulability Emerging Therapies
12. Hypercoagulability Market Outlook
13. Country-Wise Hypercoagulability Market Analysis (2019-2032)
14. Hypercoagulability Market Access and Reimbursement of Therapies
15. Hypercoagulability Market Drivers
16. Hypercoagulability Market Barriers
17. Hypercoagulability Appendix
18. Hypercoagulability Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=hypercoagulability-market-statistics-expected-to-experience-major-growth-by-2032-according-to-delveinsight-yuhan-corp-dexa-medica-group-asahi-kasei-pharma-kyowa-kirin-co-takeda-octapharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Hypercoagulability Market Statistics Expected to Experience Major Growth by 2032, According to DelveInsight | Yuhan Corp, Dexa Medica Group, Asahi Kasei Pharma, Kyowa Kirin Co., Takeda, Octapharma here
News-ID: 4040878 • Views: …
More Releases from ABNewswire

"The Magic of Setting Goals: How Your Dream Can Come True" by Lynn Rossi
Do your dreams feel as if they will remain dreams, not a part of your reality? The Magic of Setting Goals: How Your Dream Can Come True by Lynn Rossi is the guidebook you need. It is filled with practical strategies to overcome obstacles that could be limiting your success. Lynn explores what determines your success, and how to find support during challenges, as well as how you will change…

Your Journey Counseling and Wellness Recognized as a Top-Rated Therapy & Mental …
ATLANTA & DECATUR, GA - September 9, 2025 - Your Journey Counseling & Wellness [https://yjcandwellness.com/] (YJC & Wellness) announced it has been recognized as a top-rated counseling and wellness provider serving the Atlanta (Buckhead) and Decatur communities. The recognition reflects consistent five-star client feedback, strong access to care, and an insurance-friendly model across both locations.
"Being top-rated to us means neighbors trust us with their mental health-and we honor that by…

Chestnut Funeral Home Encourages Gainesville Residents to Pre-Plan Cremation Ser …
Chestnut Funeral Home, a respected provider of funeral and cremation services in Gainesville, Florida, is encouraging local residents to consider the lasting benefits of pre-planning cremation services.
Gainesville, FL - September 9, 2025 - Chestnut Funeral Home, a respected provider of funeral and cremation services in Gainesville, Florida, is encouraging local residents to consider the lasting benefits of pre-planning cremation services. With more families choosing cremation as a flexible and meaningful…

Hearthfire Holdings Announces Promotion of Peter McDaniel to Chief Development O …
Philadelphia, PA - September 9, 2025 - Hearthfire Holdings [https://hfirecapital.com/], a leader in direct access institutional-grade self-storage assets, announces the promotion of Peter (Pete) McDaniel [https://www.linkedin.com/in/peter-mcdaniel-a54134152/] to the position of Chief Development Officer (CDO) following his successful tenure as Director of Construction at Hearthfire Holdings.
"Pete's promotion is a testament to his ability to create an expandable construction system for the company and his strong commitment to Hearthfire's core values," states…
More Releases for Hypercoagulability
Hypercoagulability Market is expected to reach USD 32.8 billion by 2034
Hypercoagulability, often referred to as thrombophilia, is a condition in which the blood has an increased tendency to clot. This predisposition may be inherited (genetic thrombophilia such as Factor V Leiden mutation, prothrombin gene mutation, protein C/S deficiency) or acquired (from conditions like cancer, autoimmune diseases, pregnancy, or prolonged immobility). While coagulation is vital for preventing excessive bleeding, hypercoagulability significantly raises the risk of deep vein thrombosis (DVT), pulmonary embolism…
Vernal Keratoconjunctivitis Market Growth to Accelerate in Forecast Period (2024 …
DelveInsight's "Vernal Keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Vernal Keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal Keratoconjunctivitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Vernal Keratoconjunctivitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Vernal Keratoconjunctivitis Market Forecast
https://www.delveinsight.com/sample-request/vernal-keratoconjunctivitis-market-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
Understanding the CAGR Trends: Global Point of Care Diagnostics Market to grow a …
As per DelveInsight's assessment, the Point of Care Diagnostics Market is expected to grow at an immense pace in the coming years owing to the The increasing prevalence of pandemic such as COVID-19, Pre- and post-operation and some few of the other applications where Point of Care Diagnostics have been used, which is expected to drive the demand for Point of Care Diagnostics in the upcoming years.
DelveInsight's "Point of Care…
Tinnitus Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, an …
Tinnitus pipeline constitutes 7+ key companies continuously working towards developing 8+ Tinnitus treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Tinnitus Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Tinnitus Market.
The Tinnitus Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical…
Global Biologics Market Projected to Grow at 9.59% CAGR by 2030, Reports DelveIn …
As per DelveInsight's assessment, the Biologics Market is expected to grow at an immense pace in the coming years owing to the The increasing prevalence of pandemic such as COVID-19, Pre- and post-operation and some few of the other applications where Biologics have been used, which is expected to drive the demand for Biologics in the upcoming years.
DelveInsight's "Biologics Market" report provides the current and forecast market outlook, forthcoming device…
Hypercoagulability Treatment Market to grow at a CAGR of over 6.8% from 2023 to …
Newark, New Castle, USA - Hypercoagulability Treatment Market Analysis 2023 | Business Opportunities, Pricing Strategy, Forthcoming opportunities planning, Market-specific challenges, Globally Market Key Facts are coverd in this report by Growth Plus Reports | 100+ Report Pages
Hypercoagulability Treatment Market 2023 with 100+ Pages Report and enhance with extents shares into sub-counties are covered in this market. Hypercoagulability Treatment Market conditions can be influenced by a wide range of factors, including…